An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria

References

• Bousquet J, Burney PG, Zuberbier T et al. GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma ‘epidemic’. Allergy64, 969–977 (2009).
   PubMed Web of Science ®Google Scholar
• Léger D, Annesi-Maesano I, Carat F et al. Allergic rhinitis and its consequences on quality of sleep. An unexplored area. Arch. Intern. Med.166, 1744–1748 (2006).
   PubMedGoogle Scholar
• Jáuregui I, Mullol J, Dávila I et al. Allergic rhinitis and school performance. J. Investig. Allergol. Clin. Immunol.19(Suppl. 1), S32–S39 (2009).
   PubMed Web of Science ®Google Scholar
• Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis: a critical evaluation of the literature. Pharmacoeconomics22, 345–361 (2004).
   PubMed Web of Science ®Google Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J. Allergy Clin. Immunol.126, 466–476 (2010).
   PubMed Web of Science ®Google Scholar
• Gregory C, Cifaldi M, Tanner LA. Targeted intervention programs: creating a customized practice model to improve the treatment of allergic rhinitis in a managed care population. Am. J. Manag. Care5, 485–496 (1999).
   PubMedGoogle Scholar
• Zuberbier T, Maurer M. Urticaria: Current opinions about etiology, diagnosis and therapy. Acta Derm. Venereol.87, 196–205 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrer M, Kaplan AP. Progress and challenges in the understanding of chronic urticaria. Allergy Asthma Clin. Immunol.3, 31–35 (2007).
   PubMedGoogle Scholar
• Maurer M, Ortonne JP, Zuberbier T. Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. Br. J. Dermatol.160, 633–641 (2009).
   PubMed Web of Science ®Google Scholar
• Emanuel MB. Histamine and the antiallergic antihistamines: a history of their discoveries. Clin. Exp. Allergy29(Suppl. 3), S1–S11 (1999).
   PubMed Web of Science ®Google Scholar
• Nicholson AN. Central effects of H1 and H2 antihistamines. Aviat. Space Environ. Med.56, 293–298 (1985).
   PubMed Web of Science ®Google Scholar
• Simons FE. Advances in H1-antihistamines. N. Engl. J. Med.351, 2203–2217 (2004).
   PubMed Web of Science ®Google Scholar
• Church MK, Maurer M, Simons FER et al. Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy65, 459–466 (2010).
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Asero R, Bindslev-Jensen C et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy64, 1427–1443 (2009).
   PubMed Web of Science ®Google Scholar
• Ferrer M, Sastre J, Jáuregui I et al. Effect of antihistamine dose escalation in chronic urticaria. J. Investig. Allergol. Clin. Immunol.21(Suppl. 3), S34–S39 (2011).
   PubMed Web of Science ®Google Scholar
• Woosley RL. Cardiac actions of antihistamines. Ann. Rev. Pharmacol. Toxicol.36, 233–252 (1996).
   PubMed Web of Science ®Google Scholar
• Maurer M, Weller K, Bindslev-Jensen C et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN Task Force report. Allergy66, 317–330 (2011).
   PubMed Web of Science ®Google Scholar
• Marple BF, Fornadley JA, Patel AA et al. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol. Head Neck Surg.136(Suppl. 6), S107–S124 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrer E, Pandian R, Bolós J, Castañer R. Bilastine. Drugs Future35(2), 98–105 (2010).
   Google Scholar
• Holgate ST, Canonica GW, Simons FER et al. Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clin. Exp. Allergy33, 1305–1324 (2003).
   PubMed Web of Science ®Google Scholar
• Corcóstegui R, Labeaga L, Innerarity A et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist. Receptor selectivity and in vitro antihistaminic activity. Drugs RD6(6), 371–384 (2005).
   PubMedGoogle Scholar
• Corcóstegui R, Labeaga L, Innerárity A et al.In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs RD7(4), 219–231 (2006).
   PubMedGoogle Scholar
• Alvarez-Mon M, San Antonio E, Lucero M et al. Bilastine, a novel antihistamine that preferentially inhibits histamine and interleukin-4 release from human mast cells and granulocytes. Allergy64(Suppl. 90), 555 (2009).
   Google Scholar
• Sologuren A, Valiente R, Crean C, McLaverty D. Relationship of dose to inhibiton of wheal and flare for 5 doses of bilastine and 10 mg cetirizine. Presented at: American College of Clinical Pharmacology (ACCP) 36th Annual Meeting. San Francisco, CA, USA, 9–11 September 2007 (Abstract 69).
   Google Scholar
• Jauregizar N, de la Fuente L, Lucero ML, Sologuren A, Leal N, Rodriguez M. Pharmacokinetic–pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin. Pharmacokinet.48(8), 543–554 (2009).
   PubMed Web of Science ®Google Scholar
• Sologuren A, Lucero ML, Valiente R et al. Human mass balance with [14C]-bilastine following oral administration to healthy volunteers. Basic Clin. Pharmacol. Toxicol.105(Suppl. 1), Abstract TP85 (2009).
   Google Scholar
• Crean C, Valiente R, Sologuren A, McLaverty D. Effect of grapefruit juice on the pharmacokinetics of bilastine. J. Clin. Pharmacol.47(9), 71 (2007).
   Google Scholar
• Bailey DG. Fruit juice inhibition of uptake transport: a new type of food–drug interaction. Br. J. Clin. Pharmacol.70, 645–655 (2010).
   PubMed Web of Science ®Google Scholar
• Crean C, Sologuren A, Valiente R, McLaverty D. The drug–drug interaction of ketoconazole on bilastine pharmacokinetics. Basic Clin. Pharmacol. Toxicol.101(Suppl. 1), Abstract P253 (2007).
   Google Scholar
• Bachert C, Kuna P, Zuberbier T. Bilastine in allergic rhinoconjunctivitis and urticaria. Allergy65(Suppl. 93), S1–S13 (2010).
   Web of Science ®Google Scholar
• Garcia-Gea C, Clos S, Antonioli DA et al. Crossover, randomised, double-blind, double-dummy, placebo and positive standard-controlled, unicenter clinial trial to assess the possible interaction on CNS effects between bilastine (20 mg and 80 mg ) and alcohol (0.8 g/kg) after single simultaneous administration in healthy subjects. Basic Clin. Pharmacol. Toxicol.99(Suppl. 1), 30 (2006).
   Google Scholar
• Church MK. Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Exp. Opin. Drug Saf.10(5), 779–793 (2011).
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, Lemell P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna challenge chamber. Inflamm. Res.59, 391–398 (2010).
   PubMed Web of Science ®Google Scholar
• Bachert C, Kuna P, Sanquer F et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy64, 158–165 (2009).
   PubMed Web of Science ®Google Scholar
• Kuna P, Bachert C, Nowacki Z et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin. Exp. Allergy39, 1338–1347 (2009).
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Oanta A, Bogacka E et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy65(4), 516–528 (2010).
   PubMed Web of Science ®Google Scholar
• Taglialatela M, Pannaccione A, Castaldo P et al. Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol. Pharmacol.54, 113–121 (1998).
   PubMed Web of Science ®Google Scholar
• Tyl B, Kabbaj M, Azzam S et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J. Clin. Pharmacol. doi:10.1177/0091270011407191 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Montoro J, Sastre J, Bartra J et al. Effect of H1 antihistamines upon the central nervous system. J. Investig. Allergol. Clin. Immunol.16(Suppl. 1), S24–S28 (2006).
   PubMedGoogle Scholar
• Montoro J, Mullol J, Dávila IJ et al. Bilastine and the central nervous system. J. Investig. Allergol. Clin. Immunol.21(Suppl. 3), S9–S15 (2011).
   PubMed Web of Science ®Google Scholar
• García-Gea C, Martínez-Colomer J, Antonijoan RM et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J. Clin. Psychopharmacol.28(6), 675–685 (2008).
   PubMed Web of Science ®Google Scholar
• Conen S, Theunissen EL, Van Oers et al. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J. Psychopharmacol. doi:10.1177/0269881110382467 (2010) (Epub ahead of print).
   PubMedGoogle Scholar